RP16035

N/A

Report date: 2026/01/07 10:16:08
NME

Base Information

Drug NameRP16035
Drug Alias NameRP-16035
ClassificationSmall molecules
Mechanisms of ActionCyclin-dependent kinase 2 inhibitorsCyclin-dependent kinase 9 inhibitors
TargetsCyclin-dependent kinase 2Cyclin-dependent kinase 9
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRhizen Pharmaceuticals AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRhizen Pharmaceuticals AG
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A